Galmed Pharmaceuticals (NASDAQ: GLMD) Undergoes Reverse Stock Split: What Investors Need to Know

• Galmed Pharmaceuticals (NASDAQ: GLMD) executed an 8-for-1 reverse stock split on August 19, 2026, consolidating shares without altering total company or investor ownership value.
• Post-split, Galmed Pharmaceuticals' stock price saw increased activity, crossing its 50-day moving average and reaching a high of $5.45, with a market capitalization of $39.73 million.
• Despite recent price movement, analyst sentiment remains cautious, with a consensus "Sell" rating from equities research analysts.

Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for liver diseases and related metabolic conditions. On August 19, 2026, the company performed an 8-for-1 reverse stock split. This action consolidates the number of existing shares into fewer, higher-priced shares.

A reverse stock split reduces the total number of a company's shares in the market. For Galmed Pharmaceuticals, every eight shares held by an investor were combined into one new share. While this increases the price per share, it does not change the company's total value or an investor's total ownership value.

Following the split, Galmed Pharmaceuticals' stock price showed notable activity. As highlighted by Defense World, shares crossed above their 50-day moving average of $4.53, reaching a high of $5.45. The 50-day moving average is a stock's average closing price over the last 50 days, used by traders to gauge price trends.

The stock closed the day at $4.77 with a trading volume of 225,638 shares. This activity gives the company a market capitalization of $39.73 million. Market capitalization represents the total dollar value of a company's outstanding shares and is a measure of its size.

Despite the recent price increase, analyst sentiment remains cautious. Weiss Ratings reiterated a "sell (e+)" rating for Galmed Pharmaceuticals. This view is consistent with data from MarketBeat.com, which shows a consensus "Sell" rating from equities research analysts, suggesting they do not expect the stock to outperform.